Angiotensin II (AngII): Complete Research Profile — AT1R/AT2R Signaling, RAAS Cascade, Cardiovascular Fibrosis, and Biased Agonism Research (2026)

# Angiotensin II (AngII): Complete Research Profile

AT1R/AT2R Signaling, RAAS Cascade, Cardiovascular Fibrosis, and Biased Agonism Research (2026)

> Research Use Only (RUO): Angiotensin II is a research peptide used exclusively for laboratory investigation of receptor pharmacology, signal transduction, cardiovascular biology, and related disciplines. This article is for educational and scientific reference purposes only.

Angiotensin II (AngII) is an octapeptide and the primary bioactive effector of the renin-angiotensin-aldosterone system (RAAS) — one of the most studied hormonal axes in all of biomedical research. Despite its compact eight-amino-acid sequence (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe), AngII orchestrates a remarkable range of physiological functions spanning vasoconstriction, aldosterone secretion, sodium homeostasis, cardiac remodeling, renal filtration, and neuroendocrine regulation. It achieves this breadth through two pharmacologically distinct receptor subtypes — AT1R and AT2R — that in many contexts produce opposing biological outcomes.

For researchers, AngII is both a subject of study and an indispensable laboratory tool. Its ability to activate well-defined GPCR signaling cascades, promote cellular hypertrophy and fibrosis, and serve as a scaffold for structure-activity relationship (SAR) studies of biased agonism makes it one of the most productive peptides in cardiovascular pharmacology. This profile covers AngII structure, biosynthesis, receptor pharmacology, downstream signaling, tissue-level biology, and contemporary research applications.

---

Molecular Structure and Biosynthesis

The Octapeptide Scaffold

Angiotensin II is an octapeptide with the sequence H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH (single-letter: DRVYIHPF), molecular weight approximately 1046 Da. The C-terminal phenylalanine at position 8 is indispensable for high-affinity AT1R binding, a structural insight that has guided decades of SAR research and the development of Ang II analogs.

The peptide exists as a linear structure but adopts a compact conformation upon receptor binding. The N-terminal aspartate (position 1) and the imidazole ring of histidine (position 6) form key contacts within the AT1R binding pocket. Substitution at position 1 with sarcosine (N-methylglycine) generates [Sar1]AngII — an analog widely used in research to probe AT1R pharmacology because sarcosine confers resistance to aminopeptidase degradation.

RAAS Biosynthetic Cascade

Angiotensin II sits at the apex of the classical RAAS proteolytic cascade:

1. Angiotensinogen (AGT) — a ~55 kDa α2-globulin glycoprotein constitutively secreted by the liver (and locally expressed in kidney, brain, adipose tissue) — serves as the obligate AngII precursor.

2. Renin — an aspartyl protease secreted by juxtaglomerular cells of the renal afferent arteriole — cleaves the Leu10–Val11 bond of angiotensinogen to release the decapeptide angiotensin I (AngI, DRVYIHPFHL). Renin release is stimulated by renal hypoperfusion, sympathetic β1-adrenoceptor activation, and hyponatremia; it is the rate-limiting step of RAAS activation.

3. Angiotensin-converting enzyme (ACE) — a zinc metalloprotease expressed on vascular endothelial surfaces, most abundantly in the pulmonary circulation — removes the C-terminal dipeptide His-Leu from AngI, generating the octapeptide angiotensin II.

Angiotensin I itself has no appreciable biological activity and functions purely as an AngII precursor. Once formed, AngII has a plasma half-life of approximately 15–60 seconds, rapidly degraded by angiotensinases (aminopeptidases A and N) into angiotensin III (RVYIHPF), angiotensin IV (VYIHPF), and the receptor-active heptapeptide angiotensin-(1-7) [generated by ACE2 from AngII].

The ACE2 Counter-Axis

ACE2 — a monocarboxypeptidase upregulated in the heart, kidney, and lung — cleaves the C-terminal phenylalanine from AngII to produce angiotensin-(1-7), which acts at the Mas receptor to exert vasodilatory, anti-fibrotic, and cardioprotective effects that broadly oppose AngII's AT1R-driven actions. This counter-regulatory axis is covered in depth in the dedicated [Angiotensin-(1-7) research profile on this platform.]

The classical RAAS (renin → ACE → AngII → AT1R) and the alternative axis (ACE2 → Ang1-7 → Mas) together constitute a yin-yang system, with the balance between them a major determinant of cardiovascular and renal homeostasis.

---

Receptor Pharmacology: AT1R and AT2R

AT1R: The Dominant Signaling Receptor

The angiotensin type 1 receptor (AT1R) — encoded by the AGTR1 gene, ~359 amino acids, Gαq-coupled — mediates the vast majority of AngII's classical physiological and pathological effects. AT1R is expressed ubiquitously: vascular smooth muscle, endothelium, heart, kidney (glomerular mesangial cells, proximal tubule, juxtaglomerular apparatus), adrenal cortex, brain (subfornical organ, paraventricular nucleus), liver, and lung.

Key AT1R pharmacological characteristics:

• •High affinity for AngII (Kd ~1 nM)
• •Constitutive basal activity (inverse agonism is pharmacologically relevant)
• •Homo- and heterodimerization with AT2R and other GPCRs
• •Internalization and recycling upon AngII stimulation
• •Stretch-activation (mechanical AngII-independent activation in cardiac myocytes under pressure overload)
• •Regulation by AT1-AAs (autoantibodies) — relevant to preeclampsia research models

AT2R: The Counter-Regulatory Receptor

The angiotensin type 2 receptor (AT2R) — encoded by AGTR2, ~363 amino acids, primarily Giα/nitric oxide coupled — is most highly expressed during fetal development and declines postnatally. In adults, AT2R expression is highest in the adrenal medulla, uterus, heart (induced during failure), kidney interstitium, brain, and vasculature under pathological conditions.

AT2R opposes many AT1R-driven effects:

• •Vasodilation via nitric oxide/cGMP
• •Anti-proliferative, pro-apoptotic, anti-fibrotic actions
• •Counter-regulation of AT1R-driven hypertension and cardiac hypertrophy
• •Neuroprotection and neural differentiation
• •Anti-inflammatory and pro-resolving effects in experimental models

The selective AT2R agonist compound 21 (C21) — a non-peptide small molecule — has advanced to Phase II clinical trials for idiopathic pulmonary fibrosis, validating AT2R as a druggable target. The 2020 chemical evolution review (PMID: 32340100) details how SAR work progressed from AngII octapeptide frameworks through truncated peptides and peptidomimetics to achieve drug-like AT2R selectivity.

---

AT1R Signaling: Mechanistic Depth

Canonical Gαq/PLC/PKC Pathway

Upon AngII binding, AT1R undergoes conformational activation and couples to Gαq, which activates phospholipase C-β (PLCβ). PLCβ hydrolyzes PIP2 to generate:

• •IP3 → triggers Ca2+ release from ER via IP3R → activates calmodulin/MLCK, calcineurin/NFAT (hypertrophy)
• •DAG → activates protein kinase C (PKC) isoforms (α, β, δ, ε) → phosphorylates downstream effectors including EGFR, c-Src

Intracellular calcium release drives immediate vasoconstriction (vascular smooth muscle contraction via Ca2+-calmodulin/myosin light chain kinase) and is a proximal trigger for cardiac hypertrophic gene programs.

MAPK/ERK Transactivation

AT1R robustly activates ERK1/2 and p38 MAPK — largely via a Gβγ-mediated transactivation of the EGFR (c-Src → MMP activation → HB-EGF shedding → EGFR phosphorylation → Ras/Raf/MEK/ERK). ERK1/2 activation promotes:

• •Vascular smooth muscle cell proliferation and migration
• •Cardiac myocyte hypertrophy (translocation to nucleus → AP-1/Elk-1 transcription)
• •Inflammatory gene expression

p38 MAPK mediates stress responses and contributes to AngII-induced cardiomyocyte apoptosis and fibroblast activation.

NADPH Oxidase-Derived Reactive Oxygen Species

Angiotensin II is one of the most potent physiological activators of NADPH oxidase (NOX). AT1R stimulation activates NOX2 (vascular and cardiac) and NOX4 (renal, endothelial, cardiac) via Rac1/Rac2 GTPases and c-Src, generating superoxide (O2•-), which rapidly dismutates to H2O2.

ROS production drives:

• •Oxidative inactivation of NO (→ impaired vasodilation, endothelial dysfunction)
• •NFκB activation → inflammatory cytokines (TNF-α, IL-6, MCP-1)
• •ERK1/2 and Akt/mTOR phosphorylation (growth, survival)
• •TGF-β1 induction → fibroblast-to-myofibroblast transition → collagen deposition
• •Mitochondrial dysfunction and cardiomyocyte apoptosis

NOX-derived ROS is a central mechanistic hub through which AngII produces cardiac hypertrophy, vascular remodeling, and organ fibrosis.

β-Arrestin Signaling: Biased Agonism Frontier

Beyond G-protein coupling, AT1R undergoes GRK (G protein-coupled receptor kinase)-mediated phosphorylation and β-arrestin (βarr1/βarr2) recruitment. β-Arrestin serves dual roles:

1. Desensitization: sterically blocks further G-protein coupling, promotes receptor internalization

2. Signaling scaffold: recruits ERK1/2, Src, PI3K, and other kinases independently of G-protein signaling

The concept of biased agonism (functional selectivity) at AT1R has generated intense research interest: can compounds selectively engage β-arrestin pathways while sparing Gαq-driven vasoconstriction and oxidative stress? Research tools including [Sar1,Ile4,Ile8]-AngII (SII), TRV023, and TRV027 (a β-arrestin-biased AT1R ligand) have been developed and studied in cardiovascular models. A 2024 review (PMID: 39270918) details the clinical translation challenges — peptide half-lives limit therapeutic utility, and a phase IIb trial of TRV027 in acute heart failure did not achieve primary endpoints — but the concept remains pharmacologically valuable for dissecting AT1R signaling biology.

Cyclic AngII analogs (reviewed in PMID: 29684376) have been especially useful for probing which receptor conformations engage distinct β-arrestin conformations, advancing the structural pharmacology of biased GPCR signaling broadly.

---

Cardiovascular Biology

Vascular Effects

At the vasculature, AngII/AT1R is the dominant acute vasoconstrictor:

• •Direct smooth muscle contraction: via Gαq/IP3/Ca2+ and PKC-mediated MLCK phosphorylation; AngII is 40× more potent than norepinephrine on a molar basis in some vascular beds
• •Endothelial dysfunction: NOX2-derived superoxide scavenges endothelial NO → impaired vasodilation
• •Vascular inflammation: upregulation of ICAM-1, VCAM-1, MCP-1 → monocyte recruitment → early atherosclerotic lesion formation
• •Vascular smooth muscle cell (VSMC) proliferation and migration: via ERK1/2 and PDGFR transactivation → neointimal hyperplasia
• •Platelet activation: AT1R expressed on platelets mediates AngII-induced aggregation enhancement

At the AT2R, the counter-regulatory vasodilation occurs predominantly via NO/cGMP in vascular endothelium and smooth muscle, bradykinin release, and activation of SHP-1 phosphatases that antagonize AT1R-driven MAPK.

Cardiac Hypertrophy and Fibrosis

Angiotensin II is a primary driver of pathological cardiac remodeling through multiple convergent mechanisms:

Cardiomyocyte hypertrophy:

• •Gαq → calcineurin/NFAT → fetal gene program re-expression (β-MHC, ANP, skeletal α-actin)
• •ERK1/2/p90RSK → ribosomal activation → protein synthesis
• •PI3K/Akt/mTOR → protein anabolism
• •NOX-derived ROS → redox-sensitive hypertrophic transcription
• •Mechanical stretch-activated AT1R (pressure overload model) — a major research insight showing AngII-independent AT1R activation

Cardiac fibrosis:

• •Direct activation of cardiac fibroblasts → myofibroblast differentiation → ECM deposition (collagen types I and III)
• •AngII → TGF-β1 induction → SMAD2/3 signaling → fibrotic gene transcription
• •NOX4-derived H2O2 → αSMA expression, fibroblast activation
• •CTGF (connective tissue growth factor) induction
• •Macrophage recruitment (via MCP-1) → additional TGF-β secretion

Chronic AngII infusion via osmotic minipump in rodent models remains one of the most widely used experimental paradigms for inducing cardiac hypertrophy, aortic aneurysm, and renal damage in cardiovascular research.

---

Renal Biology

The kidney is a primary target of AngII actions:

Hemodynamic effects:

• •Constriction of the afferent and (more potently) efferent arteriole → increased glomerular hydrostatic pressure → maintains GFR during hypoperfusion
• •Promotes mesangial cell contraction → decreases glomerular filtration surface
• •At pathologically elevated concentrations: efferent constriction → glomerular hypertension → eventual podocyte injury and proteinuria

Tubular sodium transport:

• •AT1R on proximal tubule cells → activates Na+/H+ exchanger (NHE3) and Na+-K+-ATPase → enhanced sodium and water reabsorption
• •Stimulates aldosterone secretion from the adrenal zona glomerulosa → distal nephron ENaC upregulation → additional Na+ retention → volume expansion and blood pressure elevation

Renal fibrosis:

• •A 2023 study (DOI: 10.1161/HYPERTENSIONAHA.122.18657) showed AngII activates FGFR1/STAT3 signaling in renal tubular epithelial cells → TGF-β1 and COL-4 induction → interstitial fibrosis
• •TGF-β1 induction → EMT (epithelial-mesenchymal transition) of tubular cells — a central mechanism of CKD progression in experimental models

---

Brain and Neuroendocrine Effects

Angiotensin II acts on circumventricular organs (lacking blood-brain barrier) as well as intrinsic brain RAAS:

Subfornical organ (SFO) and OVLT: AT1R-expressing neurons respond to circulating AngII → drinking behavior (dipsogenesis) → vasopressin secretion from the posterior pituitary → water retention

Paraventricular nucleus (PVN): AngII → sympathetic nervous system activation → norepinephrine release → peripheral vasoconstriction and tachycardia

Area postrema: Emetic responses, blood pressure control integration

Neuroinflammation: Brain RAAS contributes to neuroinflammatory cascades; AT1R blockade in rodent models attenuates microglial activation and cytokine release. AT2R activation in the brain promotes neuroprotection and neurite outgrowth, opening research avenues in neurodegenerative disease models.

---

Adrenal and Endocrine Signaling

The adrenal zona glomerulosa expresses extremely high AT1R density. AngII is the primary peptide stimulus for aldosterone synthase (CYP11B2) expression and aldosterone biosynthesis. The resulting aldosterone → mineralocorticoid receptor (MR) activation → ENaC and Na+/K+-ATPase upregulation in the distal nephron and colon → Na+ retention, K+ excretion, blood pressure elevation.

AngII also stimulates catecholamine release from the adrenal medulla (AT1R on chromaffin cells), and modulates cortisol production through indirect mechanisms.

Hyperaldosteronism driven by autonomous AngII sensitivity (as occurs in primary aldosteronism and some adrenal adenomas) is a major research model for studying mineralocorticoid excess, and AngII infusion paradigms are used experimentally to model aldosterone-mediated cardiac and renal fibrosis independently of blood pressure effects (using renin inhibitor co-infusion).

---

Research Tools and Peptide Analogs

Angiotensin II's compact octapeptide scaffold has made it an ideal template for generating receptor-selective research tools:

Classic Research Analogs

Biased Agonism Tools

• •TRV023 / TRV027: Peptide-based β-arrestin-biased AT1R agonists; clinical-stage probes for heart failure research
• •SII-AngII: The canonical G-protein-silent, β-arrestin-selective AT1R probe; essential for dissecting pathway-specific biology
• •Cyclic AngII analogs (e.g., [Sar1Hcy3,5]AngII): Conformationally constrained tools for probing receptor activation state

AT2R Selective Tools

• •C21 (compound 21): The first drug-like, orally active non-peptide AT2R agonist; Phase II in IPF; widely used for AT2R biology in fibrosis, neuroprotection, metabolic, and cardiovascular research
• •PD123319: Selective non-peptide AT2R antagonist; essential counterpart to losartan (AT1R antagonist) for delineating receptor contributions

Pharmacological Blockade Tools

• •Losartan, valsartan (ARBs): Competitive AT1R antagonists; widely used to isolate AT1R contributions in research models
• •Captopril, enalaprilat (ACE inhibitors): Inhibit AngII generation; used to investigate RAAS-dependent effects
• •Aliskiren (renin inhibitor): Direct renin inhibition; allows upstream RAAS blockade

---

Angiotensin Peptide Family in Research Context

Angiotensin II is the central node in a family of biologically active fragments:

Angiotensin III has approximately 40% of AngII's vasoconstrictor potency but is equipotent in stimulating aldosterone secretion, suggesting differential receptor interactions or tissue-specific processing. Angiotensin IV's AT4R (identified as insulin-regulated aminopeptidase, IRAP) engagement is a distinct research area with implications for memory and hippocampal blood flow.

---

Experimental Models Using Angiotensin II

Osmotic minipump AngII infusion: The workhorse model for studying RAAS-mediated cardiovascular and renal disease. Subcutaneous delivery of AngII (typically 400–1000 ng/kg/min in mice) over 2–4 weeks induces: hypertension, cardiac hypertrophy and fibrosis, aortic aneurysm and dissection (in apoE-/- mice), renal injury, and vascular inflammation.

In vitro signaling assays: AngII at 100 nM–1 μM is widely applied to primary cardiomyocytes, VSMCs, mesangial cells, renal tubular cells, and fibroblasts to stimulate hypertrophic, proliferative, and fibrotic gene programs.

Receptor pharmacology: Radioligand binding with [125I]-AngII; BRET/FRET-based β-arrestin recruitment assays; IP1 accumulation (AT1R/Gq); cGMP measurement (AT2R/NOS).

Biased agonism screening: HTRF-based assay panels measuring parallel Gq (IP1), Gi (cAMP), β-arrestin-1, and β-arrestin-2 recruitment to calculate bias factors relative to the reference agonist (AngII).

---

---

Related Research Tools and Reading

Researchers studying the AngII signaling axis may also find these platform resources useful:

• •Angiotensin III (1-7) — the downstream RAAS metabolite research reagent, useful for comparative AT1R/AT2R/Mas-receptor signaling studies.
• •Angiotensinogen (1-13), human — the upstream RAAS precursor substrate for renin cleavage studies.
• •ANP (1-28), human — the natriuretic peptide counter-regulator to AngII-driven vasoconstriction, frequently used as a comparator in cardiovascular signaling assays.
• •SS-31 (Elamipretide) — a mitochondria-targeted research peptide relevant to the oxidative-stress and mitochondrial-dysfunction arm of AngII-driven cardiac fibrosis research.
• •Natriuretic Peptides (ANP, BNP, CNP): Cardiac Hormone Family Research Profile — a companion research profile covering the RAAS-opposing peptide family.
• •TGF-β1 Signaling, EMT, and Fibrosis Research Inhibitors — deeper mechanistic coverage of the downstream fibrotic signaling cascade AngII engages via AT1R.
• •Use the Peptide Comparison Tool to benchmark supplier pricing and purity across RAAS-pathway research reagents.

Comparative Research Applications

Angiotensin II research protocols often benefit from cross-compound analysis. Researchers working with Angiotensin II frequently also investigate related regulatory pathways and complementary peptides that can provide mechanistic context or synergistic effects in their experimental design.

Research protocol optimization strategies:

• •Dose-response modeling against similar compound classes for regulatory system mapping
• •Combination protocols with complementary regulatory peptides for broader biological pathway coverage
• •Temporal analysis comparing onset/offset profiles across related compounds
• •Cross-tissue bioavailability assessment through multiplexed research designs

For researchers seeking to optimize protocol design efficiency, explore our Live Peptide Comparison Tool to model cost-benefit profiles across multiple compounds, and use the Peptide Stack Builder to design multi-compound research protocols.

Frequently Asked Questions

Is Angiotensin II the same as the blood pressure medication class "ACE inhibitors" or "ARBs"?

No. AngII is the endogenous peptide hormone itself; ACE inhibitors block its synthesis and ARBs (angiotensin receptor blockers) block AT1R pharmacologically. Research-grade AngII peptide is used as a stimulus/reagent in laboratory signaling assays, not as a therapeutic agent — it is for research use only and is not intended for human or animal administration.

Why do researchers study both AT1R and AT2R if AT1R drives most of the pathological effects?

AT2R is generally considered to oppose AT1R signaling (vasodilation, anti-fibrotic, anti-proliferative effects) and is upregulated in certain injury states, making the AT1R/AT2R balance — not AT1R alone — the object of study in biased-agonism and receptor-selectivity research.

What is "biased agonism" in the context of AngII research?

It refers to a ligand's ability to preferentially activate one downstream signaling pathway (e.g., β-arrestin recruitment) over another (e.g., Gαq coupling) at the same receptor, a concept researchers use to try to separate a receptor's beneficial and pathological signaling arms — an active area of AT1R pharmacology research referenced in the biased-agonism section above.

Are there verified suppliers for AngII-pathway research peptides on this platform?

Yes — see the linked product pages above (Angiotensin III, Angiotensinogen, ANP) for live, continuously-updated supplier listings and price comparisons for related RAAS-pathway research reagents.

---

Key Research References

1. Touyz RM, et al. "Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology." Physiol Rev. 2018;98(3):1205-1211. PMID: 29873596

2. Forrester SJ, et al. "Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology." Physiol Rev. 2018. PMC: 6335102

3. Habibi J, et al. "Angiotensin II and Cardiovascular Disease: Balancing Pathogenic and Protective Pathways." Cardiovasc Res. 2025. PMC: 12293584

4. Sato T, et al. "Implications of β-Arrestin Biased Signaling by Angiotensin II Type 1 Receptor for Cardiovascular Drug Discovery and Therapeutics." Pharmacol Ther. 2024. PMID: 39270918

5. Quoyer J, et al. "Angiotensin II Cyclic Analogs as Tools to Investigate AT1R Biased Signaling Mechanisms." Biochem Pharmacol. 2018. PMID: 29684376

6. Wan Y, et al. "Evolution of Angiotensin Peptides and Peptidomimetics as Angiotensin II Receptor Type 2 (AT2) Receptor Agonists." Biomolecules. 2020;10(4):649. PMID: 32340100

7. Rompe F, et al. "Angiotensin II Type 2 Receptor-Specific Effects on the Cardiovascular System." Curr Opin Nephrol Hypertens. 2014. PMID: 24282697

8. Jaiswal A, et al. "Pathophysiology of Angiotensin II-Mediated Hypertension, Cardiac Hypertrophy, and Failure: A Perspective from Macrophages." J Cardiovasc Pharmacol. 2024. PMID: 39682749

9. Meng XM, et al. "Modulation of Angiotensin II Signaling in the Prevention of Fibrosis." PLOS ONE. 2015. PMID: 25949522

10. Liao TD, et al. "Ang II–Induced FGFR1 Activation in Tubular Epithelial Cells Promotes Hypertensive Kidney Fibrosis." Hypertension. 2023. DOI: 10.1161/HYPERTENSIONAHA.122.18657

---

Research Summary

Angiotensin II remains one of the most productive research peptides in all of cardiovascular and renal biology. Its well-characterized receptor pharmacology — opposing AT1R-mediated pathological signaling versus AT2R-mediated counter-regulatory protection — provides a rich experimental framework for understanding GPCR signaling complexity, including the frontier of biased agonism.

As a research tool, AngII's compact octapeptide structure enables systematic structural modification to generate receptor-selective probes, biased agonists, and pharmacological antagonists. As a subject of study, AngII's central role in hypertension, cardiac hypertrophy, fibrosis, renal disease, and neuroendocrine regulation ensures it remains among the most cited peptides in the biomedical literature.

For research teams investigating cardiovascular signaling, RAAS biology, GPCR pharmacology, or organ fibrosis mechanisms, angiotensin II and its receptor system represent an exceptionally well-validated and experimentally tractable research platform.

---

For Research Use Only. Not for human or animal therapeutic use. Angiotensin II and related analogs described here are intended solely for laboratory research applications.